| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total revenues | 1,232,938 | 861,184 | - | 1,926,020 |
| Research and development | 2,345,843 | 4,177,054 | - | 3,471,216 |
| General and administrative | 1,023,821 | 945,163 | - | 854,677 |
| Total operating expenses | 3,369,664 | 5,122,217 | - | 4,325,893 |
| Loss from operations | -2,136,726 | -4,261,033 | - | -2,399,873 |
| Other income | - | 117,444 | - | - |
| Interest income | 138,064 | 128,025 | - | 91,681 |
| Loss from continuing operations before income taxes | - | - | 0 | - |
| Net loss from continuing operations | - | - | 0 | -2,308,192 |
| Net loss | -1,998,662 | -4,015,564 | - | -2,308,192 |
| Earnings per share, basic | -0.12 | -0.29 | -0.4 | -0.26 |
| Earnings per share, diluted | -0.12 | -0.29 | -0.4 | -0.26 |
| Weighted average number of shares outstanding, basic | 16,757,678 | 13,956,562 | 11,106,027 | 8,923,170 |
| Weighted average number of shares outstanding, diluted | 16,757,678 | 13,956,562 | 11,106,027 | 8,923,170 |
Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)